EICHOR
● Active Not Recruiting
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD\[s\]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (78)
| University of Alabama at Birmingham, Comprehensive Cancer Center | Birmingham, Alabama, United States | — |
| The Oncology Institute of Hope and Innovation | Cerritos, California, United States | — |
| UCLA | Los Angeles, California, United States | — |
| Montefiore Einstein Center for Cancer Care | The Bronx, New York, United States | — |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | — |
| PERSONAL Oncologia de Precisao e Personalizada | Belo Horizonte, Brazil | — |
| CIONC Centro Integrado de Oncologia de Curitiba | Curitiba, Brazil | — |
| UPCO Unidade de Pesquisa Clinica em Oncologia | Pelotas, Brazil | — |
| Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS | Porto Alegre, Brazil | — |
| Oncoclinicas Rio de Janeiro S A | Rio de Janeiro, Brazil | — |
| Instituto D Or de Pesquisa e Ensino IDOR | Rio de Janeiro, Brazil | — |
| Nucleo de Oncologia da Bahia | Salvador, Brazil | — |
+ 66 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.